NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL)

ZNTL Technical Analysis
As on 18th May 2022 ZNTL Share Price closed @ 24.07 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 54.13 & Strong Sell for SHORT-TERM with Stoploss of 47.42 we also expect STOCK to react on Following IMPORTANT LEVELS.

ZNTL Share Price

Open 25.22 Change Price %
High 25.84 1 Day -2.45 -9.24
Low 23.20 1 Week 4.65 23.94
Close 24.07 1 Month -22.51 -48.33
Volume 1297700 1 Year -27.04 -52.91
52 Week High 84.79 | 52 Week Low 17.91
NASDAQ USA Most Active Stocks
AMD 96.28 -6.04%
AAPL 140.82 -5.64%
BRQS 0.19 11.76%
SNDL 0.41 -6.82%
GNUS 0.78 13.04%
AGRI 2.92 8.96%
BBIG 3.05 6.64%
ENDP 0.62 -46.55%
NVDA 169.38 -6.82%
SOFI 7.23 2.55%
NASDAQ USA Top Gainers Stocks
NDRAW 0.03 200.00%
EYESW 0.48 92.00%
SMIHW 0.15 87.50%
ZJZZT 38.00 78.82%
THCAW 0.33 73.68%
WKSPW 0.63 57.50%
TMPMW 0.11 57.14%
BROGW 0.42 55.56%
PPHPR 0.14 55.56%
EFTRW 0.23 53.33%
NASDAQ USA Top Losers Stocks
PTRAW 0.23 -89.59%
VENAW 0.05 -50.00%
ALACW 0.01 -50.00%
BTAQW 0.01 -50.00%
ENDP 0.62 -46.55%
MDGSW 0.21 -44.74%
ALACR 0.04 -42.86%
IKNX 19.52 -42.42%
NLITW 0.09 -40.00%
ROVRW 1.30 -34.34%
Daily Charts
Intraday Charts
Whats New @
Free Analysis
ZNTL Important Levels Intraday
ZNTL Target for Month May
4th UP TARGET66.77
3rd UP TARGET53.08
2nd UP TARGET44.61
1st UP TARGET36.15
1st DOWN TARGET11.99
3rd DOWN TARGET-4.94
4th DOWN TARGET-18.63
ZNTL Weekly Target
4th UP TARGET45.77
3rd UP TARGET38.81
2nd UP TARGET34.51
1st UP TARGET30.21
1st DOWN TARGET17.93
2nd DOWN TARGET13.63
ZNTL Target for Year 2022
4th UP TARGET158.69
3rd UP TARGET115.52
2nd UP TARGET88.83
1st UP TARGET62.14
2nd DOWN TARGET-40.69
3rd DOWN TARGET-67.38
4th DOWN TARGET-110.55
ZNTL Other Details
Segment EQ
Market Capital 3592067840.00
Sector Healthcare
Industry Biotechnology
Offical website >
ZNTL Address
ZNTL Latest News
Your Comments and Response on Zentalis Pharmaceuticals Inc
ZNTL Business Profile
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. The company also develops ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York. Address: 530 Seventh Avenue, New York, NY, United States, 10018
2005-2021 All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service